Puma Biotechnology, Inc. – NASDAQ:PBYI
Founder-led company
Puma Biotechnology stock price today
$4.99
+1.91
+62.01%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Puma Biotechnology stock price monthly change
-14.21%
month
Puma Biotechnology stock price quarterly change
-14.21%
quarter
Puma Biotechnology stock price yearly change
-29.03%
year
Puma Biotechnology key metrics
Market Cap | 134.50M |
Enterprise value | 168.08M |
P/E | 13.23 |
EV/Sales | 0.73 |
EV/EBITDA | 8.01 |
Price/Sales | 0.57 |
Price/Book | 6.01 |
PEG ratio | 0.13 |
EPS | 0.32 |
Revenue | 226.62M |
EBITDA | 39.64M |
Income | 15.37M |
Revenue Q/Q | -17.07% |
Revenue Y/Y | -3.60% |
Profit margin | 0% |
Oper. margin | 13.47% |
Gross margin | 75.84% |
EBIT margin | 13.47% |
EBITDA margin | 17.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePuma Biotechnology stock price history
Puma Biotechnology stock forecast
Puma Biotechnology financial statements
| Jun 2023 | 54.56M | 2.12M | 3.9% |
|---|---|---|---|
| Sep 2023 | 56.11M | 5.79M | 10.33% |
| Dec 2023 | 72.17M | 12.26M | 17% |
| Mar 2024 | 43.76M | -4.81M | -11% |
| 2025 | 225.05M | 15.1M | 6.71% |
|---|---|---|---|
| 2026 | 229.8M | 15.55M | 6.77% |
| 2027 | 205M | -7.13M | -3.48% |
| 2028 | 200M | -11.88M | -5.94% |
Analysts Price target
Financials & Ratios estimates
| 2024-02-29 | 0.3 | 0.26 |
|---|
| Jun 2023 | 200494000 | 170.09M | 84.84% |
|---|---|---|---|
| Sep 2023 | 203605000 | 164.86M | 80.97% |
| Dec 2023 | 230528000 | 177.08M | 76.82% |
| Mar 2024 | 214149000 | 163.16M | 76.19% |
| Jun 2023 | 3.29M | -4.68M | 0 |
|---|---|---|---|
| Sep 2023 | 10.61M | 11.17M | 0 |
| Dec 2023 | 10.45M | -8.17M | 0 |
| Mar 2024 | 11.24M | -19.08M | 0 |
Puma Biotechnology alternative data
| Aug 2023 | 192 |
|---|---|
| Sep 2023 | 192 |
| Oct 2023 | 192 |
| Nov 2023 | 192 |
| Dec 2023 | 192 |
| Jan 2024 | 192 |
| Feb 2024 | 192 |
| Mar 2024 | 185 |
| Apr 2024 | 185 |
| May 2024 | 185 |
| Jun 2024 | 185 |
| Jul 2024 | 185 |
Puma Biotechnology other data
60.21%
-5.89%
of PBYI is owned by hedge funds
71
-10
27.31M
-588.22K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 25000 |
| Jan 2024 | 0 | 86125 |
| Jun 2024 | 0 | 96900 |
| Jul 2024 | 0 | 34580 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | NOUGUES MAXIMO F officer: Chief Fi.. | Common Stock | 5,295 | $3.27 | $17,309 | ||
Sale | LUDWIG JEFFREY JEROME officer: Chief Co.. | Common Stock | 6,051 | $3.27 | $19,781 | ||
Sale | HUNT DOUGLAS M officer: See Remarks | Common Stock | 4,349 | $3.27 | $14,217 | ||
Sale | AUERBACH ALAN H director, 10 perc.. | Common Stock | 18,885 | $3.27 | $61,735 | ||
Sale | WILSON TROY EDWARD director | Common Stock | 27,000 | $3.33 | $89,910 | ||
Sale | WILSON TROY EDWARD director | Common Stock | 27,000 | $3.33 | $89,910 | ||
Sale | STUGLIK BRIAN M director | Common Stock | 9,900 | $3.39 | $33,531 | ||
Sale | SENDEROWICZ ADRIAN director | Common Stock | 27,000 | $3.33 | $89,829 | ||
Sale | MOYES JAY M director | Common Stock | 22,000 | $3.34 | $73,458 | ||
Sale | DORVAL ALLISON director | Common Stock | 11,000 | $3.37 | $37,092 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Alan H. Auerbach (1970) Founder, Chairman, Pres, Chief Executive Officer & Sec. | $5,690,000 |
| Mr. Jeffrey Jerome Ludwig (1966) Chief Commercial Officer | $4,610,000 |
Mr. Douglas Hunt B.Sc., FRAPS (1965) Senior Vice President of Regulatory Affairs, Medical Writing & Project Management | $2,140,000 |
| Mr. Maximo F. Nougues (1969) Chief Financial Officer & Principal Accounting Officer | $1,630,000 |
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look
Puma Biotechnology: Alisertib Deal Alters My Strategy
Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
What's the price of Puma Biotechnology stock today?
One share of Puma Biotechnology stock can currently be purchased for approximately $4.99.
-
When is Puma Biotechnology's next earnings date?
Unfortunately, Puma Biotechnology's (PBYI) next earnings date is currently unknown.
-
Does Puma Biotechnology pay dividends?
No, Puma Biotechnology does not pay dividends.
-
How much money does Puma Biotechnology make?
Puma Biotechnology has a market capitalization of 134.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.35% to 235.64M US dollars. Puma Biotechnology earned 21.59M US dollars in net income (profit) last year or $0.26 on an earnings per share basis.
-
What is Puma Biotechnology's stock symbol?
Puma Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "PBYI".
-
What is Puma Biotechnology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Puma Biotechnology?
Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the following people:
- Mr. Alan H. Auerbach Founder, Chairman, Pres, Chief Executive Officer & Sec.(age: 55, pay: $5,690,000)
- Mr. Jeffrey Jerome Ludwig Chief Commercial Officer(age: 59, pay: $4,610,000)
- Mr. Douglas Hunt B.Sc., FRAPS Senior Vice President of Regulatory Affairs, Medical Writing & Project Management(age: 60, pay: $2,140,000)
- Mr. Maximo F. Nougues Chief Financial Officer & Principal Accounting Officer(age: 56, pay: $1,630,000)
-
Is Puma Biotechnology founder-led company?
Yes, Puma Biotechnology is a company led by its founder Mr. Alan H. Auerbach.
-
How many employees does Puma Biotechnology have?
As Jul 2024, Puma Biotechnology employs 185 workers.
-
When Puma Biotechnology went public?
Puma Biotechnology, Inc. is publicly traded company for more then 13 years since IPO on 24 Apr 2012.
-
What is Puma Biotechnology's official website?
The official website for Puma Biotechnology is pumabiotechnology.com.
-
Where are Puma Biotechnology's headquarters?
Puma Biotechnology is headquartered at 10880 Wilshire Boulevard, Los Angeles, CA.
-
How can i contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 Wilshire Boulevard, Los Angeles, CA and company can be reached via phone at 424 248 6500.
Puma Biotechnology company profile:
Puma Biotechnology, Inc.
pumabiotechnology.comExchange:
NASDAQ
Full time employees:
185
Industry:
Biotechnology
Sector:
Healthcare
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
10880 Wilshire Boulevard
Los Angeles, CA 90024
Los Angeles, CA 90024
CIK: 0001401667
ISIN: US74587V1070
CUSIP: 74587V107
